{"transactions":[{"id":1200107,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-18T18:45:05.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the total shares subject to the option shall vest on each of March 14, 2026 and March 14, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":0.89,"expiration_date":"2035-03-14","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001415889-25-008505","document":"form4-03182025_060301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588925008505/form4-03182025_060301.xml","form_type":"4"}},{"id":1200106,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-03-18T18:45:05.000Z","date":"2025-03-17","kind":"sale","planned":false,"acquired":false,"shares":4315,"price":0.65,"value":2804.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6378 to $0.6605 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":176458,"source":{"system":"sec-edgar","filing":"0001415889-25-008505","document":"form4-03182025_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588925008505/form4-03182025_060301.xml","form_type":"4"}},{"id":1280360,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-06T16:15:10.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit (\"RSU\") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."}],"balance_after":231925,"source":{"system":"sec-edgar","filing":"0001415889-25-003232","document":"form4a-02062025_040206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588925003232/form4a-02062025_040206.xml","form_type":"4/A","original_submission_date":"2023-08-28"}},{"id":1387594,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-11T16:15:07.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of the total shares subject to the option shall vest on each of April 9, 2025 and October 9, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.28,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-025026","document":"form4-10112024_041004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924025026/form4-10112024_041004.xml","form_type":"4"}},{"id":1420961,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T16:15:14.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":9530,"price":2.46,"value":23443.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive."}],"balance_after":105773,"source":{"system":"sec-edgar","filing":"0001415889-24-022427","document":"form4-08282024_040809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924022427/form4-08282024_040809.xml","form_type":"4"}},{"id":1420960,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T16:15:14.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":26183,"price":2.66,"value":69646.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":115303,"source":{"system":"sec-edgar","filing":"0001415889-24-022427","document":"form4-08282024_040809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924022427/form4-08282024_040809.xml","form_type":"4"}},{"id":1449980,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T18:10:33.000Z","date":"2024-07-23","kind":"sale","planned":false,"acquired":false,"shares":91,"price":6.98,"value":635.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."}],"balance_after":141486,"source":{"system":"sec-edgar","filing":"0001415889-24-019970","document":"form4-07232024_100729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924019970/form4-07232024_100729.xml","form_type":"4"}},{"id":1449979,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T18:10:33.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":21649,"price":7.06,"value":152841.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":141577,"source":{"system":"sec-edgar","filing":"0001415889-24-019970","document":"form4-07232024_100729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924019970/form4-07232024_100729.xml","form_type":"4"}},{"id":1569075,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T16:31:14.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":4.8,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-24-008543","document":"form4-03192024_040300.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924008543/form4-03192024_040300.xml","form_type":"4"}},{"id":1569074,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-19T16:31:14.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date."}],"balance_after":163226,"source":{"system":"sec-edgar","filing":"0001415889-24-008543","document":"form4-03192024_040300.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924008543/form4-03192024_040300.xml","form_type":"4"}},{"id":1739211,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-11-16T16:32:14.000Z","date":"2023-11-15","kind":"sale","planned":false,"acquired":false,"shares":11558,"price":2.97,"value":34327.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive."}],"balance_after":123226,"source":{"system":"sec-edgar","filing":"0001209191-23-055527","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919123055527/doc4.xml","form_type":"4"}},{"id":1739210,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-11-16T16:32:14.000Z","date":"2023-11-14","kind":"sale","planned":false,"acquired":false,"shares":22141,"price":2.93,"value":64873.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":134784,"source":{"system":"sec-edgar","filing":"0001209191-23-055527","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919123055527/doc4.xml","form_type":"4"}},{"id":1795410,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-08-28T16:39:01.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered."}],"balance_after":156925,"source":{"system":"sec-edgar","filing":"0001209191-23-047521","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919123047521/doc4.xml","form_type":"4"}},{"id":1823566,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-07-25T16:25:05.000Z","date":"2023-07-24","kind":"sale","planned":false,"acquired":false,"shares":33789,"price":4.83,"value":163200.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":81925,"source":{"system":"sec-edgar","filing":"0001209191-23-043306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919123043306/doc4.xml","form_type":"4"}},{"id":1823565,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-07-25T16:25:05.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit (\"RSU\") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall\nvest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date."}],"balance_after":115714,"source":{"system":"sec-edgar","filing":"0001209191-23-043306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919123043306/doc4.xml","form_type":"4"}},{"id":1974156,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-03T16:25:30.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":135000,"derivative":{"exercise_price":7.58,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-23-015492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919123015492/doc4.xml","form_type":"4"}},{"id":2209245,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-07-11T17:24:11.000Z","date":"2022-07-11","kind":"purchase","acquired":true,"shares":7500,"price":3.4,"value":25500.0,"ownership":{"direct":true},"balance_after":15714,"source":{"system":"sec-edgar","filing":"0001209191-22-041835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919122041835/doc4.xml","form_type":"4"}},{"id":2214885,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-07-05T16:13:59.000Z","date":"2022-07-05","kind":"purchase","acquired":true,"shares":5714,"price":2.1,"value":11999.4,"ownership":{"direct":true},"balance_after":8214,"source":{"system":"sec-edgar","filing":"0001209191-22-040616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919122040616/doc4.xml","form_type":"4"}},{"id":2372300,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-25T16:37:09.000Z","date":"2022-02-24","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":8,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-22-013202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919122013202/doc4.xml","form_type":"4"}},{"id":2679487,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-07T08:42:40.000Z","date":"2021-06-04","kind":"purchase","acquired":true,"shares":2500,"price":9.79,"value":24475.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.782\nto $9.803 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set\nforth in this footnote."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001209191-21-038481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919121038481/doc4.xml","form_type":"4"}},{"id":2814347,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-03T17:01:17.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares subject to the option shall vest on March 1, 2022 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":14.32,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-21-016972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919121016972/doc4.xml","form_type":"4"}},{"id":3233244,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-03T18:19:44.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":11.81,"expiration_date":"2030-02-26","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-20-015606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000120919120015606/doc4.xml","form_type":"4"}}]}